<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096365</url>
  </required_header>
  <id_info>
    <org_study_id>DOC-10052</org_study_id>
    <nct_id>NCT04096365</nct_id>
  </id_info>
  <brief_title>Subcostal Temporary Extracardiac Pacing Study</brief_title>
  <acronym>STEP</acronym>
  <official_title>Subcostal Temporary Extracardiac Pacing Study: Clinical Study of the AtaCor Extracardiac Pacing System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtaCor Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtaCor Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 15 subjects will be enrolled to evaluate initial safety and performance of the AtaCor&#xD;
      Temporary Pacing System. Safety will be evaluated through analysis of all Adverse Events.&#xD;
      Performance will be evaluated through (1) the incidence of successful StealthTrac Lead&#xD;
      placement using the MACH I Delivery Tool, (2) electrical performance measurements, such as&#xD;
      pacing capture thresholds, sensed R-wave amplitudes, pacing impedance and skeletal muscle&#xD;
      stimulation at rest. Appropriate sensing and pacing capture will be ascertained from ECG&#xD;
      Holter Monitor recordings during periods of in-hospital ambulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled Subjects will have both a market-released transvenous pacing lead and&#xD;
      investigational StealthTrac Temporary Pacing Lead placed and evaluated. During the placement&#xD;
      procedure, diagnostic echocardiograms will be performed to detect any new pericardial&#xD;
      effusions. Once inserted, the StealthTrac Lead will be used to deliver high rate pacing (160&#xD;
      to 220 BPM) in clinically appropriate Subjects, to demonstrate suitability for use in&#xD;
      transcatheter procedures that require brief periods of temporary pacing. Lead positions will&#xD;
      be documented using fluoroscopic images before the Subject leaves the procedure room. On the&#xD;
      following two days after the procedure, electrical performance will be evaluated in multiple&#xD;
      postures and appropriate pacing and sensing will be confirmed during activity using ECG&#xD;
      Holter monitor recordings. Subjects will also be asked patient-centric questions about their&#xD;
      experience with the StealthTrac Lead throughout the study period. Evaluations will continue&#xD;
      for a minimum of two (2) and a maximum of seven (7) days after the index procedure. Prior to&#xD;
      StealthTrac Lead removal, an X-Ray will be taken to document the final lead position and&#xD;
      diagnostic echocardiography will be performed to (1) detect any latent pericardial effusions&#xD;
      and (2) assess differences in cardiac function with intrinsic conduction and while pacing. A&#xD;
      final follow-up will be performed 25-30 days after removal to identify any latent adverse&#xD;
      events before the Subject exits the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2019</start_date>
  <completion_date type="Actual">November 7, 2019</completion_date>
  <primary_completion_date type="Actual">November 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Outcome: Number of Subjects Experiencing an Adverse Device Effect</measure>
    <time_frame>30 days</time_frame>
    <description>Safety will be evaluated through analysis of all Adverse Device Effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance Outcome: Mean Pacing Capture Threshold (V)</measure>
    <time_frame>Up to 2 days post insertion</time_frame>
    <description>Minimum current required to pacing the heart (in multiple postures)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance Outcome: Mean Pacing Impedance (Ohms)</measure>
    <time_frame>Up to 2 days post insertion</time_frame>
    <description>Impedance measured while pacing the heart (in multiple postures)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance Outcome: Mean R-Wave Amplitude (mV)</measure>
    <time_frame>Up to 2 days post insertion</time_frame>
    <description>R-Wave amplitudes measured while sensing the heart (in multiple postures)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance Outcome: % of R-R Intervals With Appropriate Pacing and Sensing During Activity</measure>
    <time_frame>Up to 2 days post insertion</time_frame>
    <description>ECG Holter Recordings obtained during periods of rest and in-hospital activity. The % of R-R intervals with appropriate pacing is calculated as the number of paced intervals that demonstrate pacing capture / the total number of pacing intervals. The % of R-R intervals with appropriate sensing is calculated as the number of intervals where pacing is appropriately delivered or inhibited (depending on the programmed settings of the pacemaker) / the total number of R-R intervals. The outcomes are presented a % of intervals and not an average of the percentages observed across patients.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Paced QRS Duration (ms)</measure>
    <time_frame>1 day after insertion</time_frame>
    <description>QRS duration measured from 12-Lead ECG</description>
  </other_outcome>
  <other_outcome>
    <measure>Echocardiographic Assessment of Left Ventricular Stroke Volume During Pacing (mL)</measure>
    <time_frame>2 days after insertion</time_frame>
    <description>Measures of cardiac function obtained from echocardiography</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Conduction Defect</condition>
  <arm_group>
    <arm_group_label>Subcostal temporary extracardiac pacing lead</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subcostal Temporary Extracardiac Pacing Lead</intervention_name>
    <description>The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.</description>
    <arm_group_label>Subcostal temporary extracardiac pacing lead</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Indicated for closed-chest cardiac invasive procedure with the potential for&#xD;
             intra-procedural or post-procedural bradycardia and willing to be hospitalized for a&#xD;
             minimum of 2 days post procedure.&#xD;
&#xD;
             Examples of such procedures include: transfemoral transcatheter aortic valve&#xD;
             replacement (TAVR), balloon valvuloplasty, permanent pacemaker implantation and pacing&#xD;
             lead extractions/revisions.&#xD;
&#xD;
          2. Physically and mentally capable of providing informed consent.&#xD;
&#xD;
          3. At least 18 years of age or of legal age to provide consent as required by local and&#xD;
             national requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindicated or clinically unsuitable for transvenous lead placement;&#xD;
&#xD;
          2. Implanted with an implantable cardioverter defibrillator (ICD) or transvenous&#xD;
             defibrillation lead at the time of enrollment;&#xD;
&#xD;
          3. History of a prior sternotomy (median or partial);&#xD;
&#xD;
          4. History of prior surgery with disruption of the lung, pericardium or connective tissue&#xD;
             between the sternum and pericardium;&#xD;
&#xD;
          5. History of significant anatomic derangement of the thorax (e.g., pectus excavatum),&#xD;
             prior chest radiation therapy or other reasons which may cause pericardial adhesions&#xD;
             or complicate the AtaCor Temporary Pacing System insertion procedure;&#xD;
&#xD;
          6. History of pericardial disease, pericarditis or mediastinitis;&#xD;
&#xD;
          7. History of chronic obstructive pulmonary disease (COPD);&#xD;
&#xD;
          8. NYHA functional classification IV at the time of enrollment;&#xD;
&#xD;
          9. History of congenital heart disease;&#xD;
&#xD;
         10. Patients with circumstances that prevent data collection or follow-up, including&#xD;
             conditions that prevent ambulation and testing in multiple postures;&#xD;
&#xD;
         11. BMI ≥ 35 kg/m2;&#xD;
&#xD;
         12. History of allergies to any study device components;&#xD;
&#xD;
         13. Pregnant or lactating (current or anticipated during study follow up); and&#xD;
&#xD;
         14. Participation in any concurrent study without prior, written approval from the&#xD;
             Sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Burke, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AtaCor Medical</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrian Ebner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanatorio Italiano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanatorio Italiano</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Paraguay</country>
  </location_countries>
  <link>
    <url>https://www.atacor.com/</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <results_first_submitted>August 6, 2020</results_first_submitted>
  <results_first_submitted_qc>February 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 3, 2021</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Temporary</keyword>
  <keyword>Ventricular</keyword>
  <keyword>Pacing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Conduction System Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT04096365/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eleven (11) of the 12 enrolled subjects underwent a StealthTrac Lead insertion procedure. One (1) subject experienced an adverse clinical event, unrelated to the StealthTrac Lead, that precluded insertion of the StealthTrac Lead and was subsequently withdrawn from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subcostal Temporary Extracardiac Pacing Lead</title>
          <description>All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.&#xD;
Subcostal Temporary Extracardiac Pacing Lead: The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subcostal Temporary Extracardiac Pacing Lead</title>
          <description>All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.&#xD;
Subcostal Temporary Extracardiac Pacing Lead: The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Mestizo / Indigenous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White / Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Paraguay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Outcome: Number of Subjects Experiencing an Adverse Device Effect</title>
        <description>Safety will be evaluated through analysis of all Adverse Device Effects</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subcostal Temporary Extracardiac Pacing Lead</title>
            <description>All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.&#xD;
Subcostal Temporary Extracardiac Pacing Lead: The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Outcome: Number of Subjects Experiencing an Adverse Device Effect</title>
          <description>Safety will be evaluated through analysis of all Adverse Device Effects</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Performance Outcome: Mean Pacing Capture Threshold (V)</title>
        <description>Minimum current required to pacing the heart (in multiple postures)</description>
        <time_frame>Up to 2 days post insertion</time_frame>
        <population>One suspected lead dislodgement prevented measurements in all 11 subjects on Day 1 and Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcostal Temporary Extracardiac Pacing Lead</title>
            <description>All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.&#xD;
Subcostal Temporary Extracardiac Pacing Lead: The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Outcome: Mean Pacing Capture Threshold (V)</title>
          <description>Minimum current required to pacing the heart (in multiple postures)</description>
          <population>One suspected lead dislodgement prevented measurements in all 11 subjects on Day 1 and Day 2.</population>
          <units>Volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Procedure)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Performance Outcome: Mean Pacing Impedance (Ohms)</title>
        <description>Impedance measured while pacing the heart (in multiple postures)</description>
        <time_frame>Up to 2 days post insertion</time_frame>
        <population>All eleven (11) Subjects contribute data on Day 0. On Day 1 and Day 2, nine (9) Subjects contribute data and two (2) Subjects do not due to a suspected lead dislodgement and one measurement out of range.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcostal Temporary Extracardiac Pacing Lead</title>
            <description>All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.&#xD;
Subcostal Temporary Extracardiac Pacing Lead: The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Outcome: Mean Pacing Impedance (Ohms)</title>
          <description>Impedance measured while pacing the heart (in multiple postures)</description>
          <population>All eleven (11) Subjects contribute data on Day 0. On Day 1 and Day 2, nine (9) Subjects contribute data and two (2) Subjects do not due to a suspected lead dislodgement and one measurement out of range.</population>
          <units>Ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="557" spread="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" spread="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Performance Outcome: Mean R-Wave Amplitude (mV)</title>
        <description>R-Wave amplitudes measured while sensing the heart (in multiple postures)</description>
        <time_frame>Up to 2 days post insertion</time_frame>
        <population>Only 4 of 11 subjects had an intrinsic rhythm for measurement of R waves.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcostal Temporary Extracardiac Pacing Lead</title>
            <description>All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.&#xD;
Subcostal Temporary Extracardiac Pacing Lead: The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Outcome: Mean R-Wave Amplitude (mV)</title>
          <description>R-Wave amplitudes measured while sensing the heart (in multiple postures)</description>
          <population>Only 4 of 11 subjects had an intrinsic rhythm for measurement of R waves.</population>
          <units>millivolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Performance Outcome: % of R-R Intervals With Appropriate Pacing and Sensing During Activity</title>
        <description>ECG Holter Recordings obtained during periods of rest and in-hospital activity. The % of R-R intervals with appropriate pacing is calculated as the number of paced intervals that demonstrate pacing capture / the total number of pacing intervals. The % of R-R intervals with appropriate sensing is calculated as the number of intervals where pacing is appropriately delivered or inhibited (depending on the programmed settings of the pacemaker) / the total number of R-R intervals. The outcomes are presented a % of intervals and not an average of the percentages observed across patients.</description>
        <time_frame>Up to 2 days post insertion</time_frame>
        <population>All subjects with a StealthTrac Lead</population>
        <group_list>
          <group group_id="O1">
            <title>Subcostal Temporary Extracardiac Pacing Lead</title>
            <description>All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.&#xD;
Subcostal Temporary Extracardiac Pacing Lead: The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Outcome: % of R-R Intervals With Appropriate Pacing and Sensing During Activity</title>
          <description>ECG Holter Recordings obtained during periods of rest and in-hospital activity. The % of R-R intervals with appropriate pacing is calculated as the number of paced intervals that demonstrate pacing capture / the total number of pacing intervals. The % of R-R intervals with appropriate sensing is calculated as the number of intervals where pacing is appropriately delivered or inhibited (depending on the programmed settings of the pacemaker) / the total number of R-R intervals. The outcomes are presented a % of intervals and not an average of the percentages observed across patients.</description>
          <population>All subjects with a StealthTrac Lead</population>
          <units>% of intervals</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pacing Capture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appropriate Sensing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Paced QRS Duration (ms)</title>
        <description>QRS duration measured from 12-Lead ECG</description>
        <time_frame>1 day after insertion</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Echocardiographic Assessment of Left Ventricular Stroke Volume During Pacing (mL)</title>
        <description>Measures of cardiac function obtained from echocardiography</description>
        <time_frame>2 days after insertion</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subcostal Temporary Extracardiac Pacing Lead</title>
          <description>All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.&#xD;
Subcostal Temporary Extracardiac Pacing Lead: The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Inability to Pace</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain (Post-Operative)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator must obtain prior written consent of Sponsor before publishing.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan Marcovecchio, Vice President, Clinical Affairs</name_or_title>
      <organization>AtaCor Medical, Inc.</organization>
      <phone>949 391 2252</phone>
      <email>alan@atacor.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

